Sodium Thiosulfate — Hope Pharmaceuticals drug label update
Hope Pharmaceuticals has updated the drug label for Sodium Thiosulfate Injection, specifying its use for the sequential treatment of acute, life-threatening cyanide poisoning in conjunction with sodium nitrite.
This update affects Hope Pharmaceuticals, clinical staff administering emergency antidotes, and regulatory professionals managing product labeling for cyanide poisoning treatments.
The update emphasizes a specific sequential administration protocol and introduces a clinical requirement for risk-benefit weighing when a diagnosis is uncertain, particularly for patients not in extremis. This suggests a regulatory focus on ensuring appropriate use of this antidote in non-emergency or diagnostic-uncertainty scenarios to mitigate potential risks.
Regulatory teams should update internal labeling records and ensure clinical protocols for acute cyanide poisoning reflect the requirement for sequential administration with sodium nitrite. Quality and clinical teams should verify that risk-benefit documentation accounts for the 'not in extremis' precaution when diagnosis is uncertain.
Sodium Thiosulfate (Hope Pharmaceuticals). 1 INDICATIONS AND USAGE Sodium Thiosulfate Injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potential risks associated with Sodium Thiosulfate Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. Sodium Thiosulfate Injection, an antidote, is indicated for sequential use with sodium nitrite for treatment of acute cyanide poisoning that is judged to be serious or life-th
Open in openFDA / FDA.gov